-
Product Insights
Inclusion Body Myositis (IBM) – Drugs In Development, 2023
Global Markets Direct’s, ‘Inclusion Body Myositis (IBM) - Drugs In Development, 2023’, provides an overview of the Inclusion Body Myositis (IBM) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (IBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Down Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Down Syndrome - Drugs In Development, 2023’, provides an overview of the Down Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Down Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Valiltramiprosate in Down Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Valiltramiprosate in Down Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Valiltramiprosate in Down SyndromeDrug Details:ALZ-801 is under development for the treatment of Alzheimer’s...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HFB-200301 in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HFB-200301 in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HFB-200301 in Melanoma Drug Details:HFB-200301 is under development for the treatment of advanced solid...
-
Product Insights
Down Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Down Syndrome Clinical Trials Overview The report provides an overview of the Down Syndrome clinical trial scenario and top-line data relating to the clinical trials. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. Key Regions ·      Europe ·      North America ·      Asia-Pacific ·      Middle East and...
-
Sector Analysis
Alzheimer’s Disease Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2030
Alzheimer’s Disease Market Overview Alzheimer’s Disease and MCI market size across the 8MM was valued at $2.2 billion in 2020 and is expected to achieve a CAGR of more than 19% during 2020-2030. AD is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. Mild cognitive impairment (MCI) is a phase of the AD continuum in which a gradually progressive cognitive decline occurs and may even become clinically relevant. Alzheimer’s Disease Market Outlook, 2020-2030...
-
Product Insights
Alzheimer Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update
Alzheimer is a progressive neurologic disorder beginning with mild memory loss. It could possibly lead to a loss of the ability to carry on a conversation and respond to the environment. The Alzheimer pipeline market research report provides comprehensive information about the Alzheimer pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – valiltramiprosate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry valiltramiprosate Drug Details ALZ-801 is under development for the treatment of Alzheimer's disease, cerebral...